08/09/2017

NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Myeloproliferative Neoplasms

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Myeloproliferative Neoplasms. These NCCN Guidelines^® are currently available as Version 1.2018. 

• Myelofibrosis
  • Hydroxyurea was added as an option for low-risk symptomatic myelofibrosis if cytoreduction would be symptomatically beneficial (MF-1).
  • Pomalidomide ± prednisone (category 3) was added as an option for the management of MF-associated anemia in patients with serum erythropoietin (EPO) ≥500 mU/mL. (MF-4)
• New algorithms were included for the management of the following subtypes:
  • Polycythemia Vera (PV-1)
  • Essential Thrombocythemia (ET-1)